Only approximately two out of 10 people in the US and three out of 10 people in Europe with certain rare, advanced blood ...

The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...

Ascletis said it has data indicating denifanstat is 98% more effective at treating acne than sarecycline, and 178% better ...

The new version of Sarclisa stems from a collaboration with Enable Injections, backed financially to the tune of €300 million ...

With Axtria Ignite 2025 just around the corner, attention turns to how the life sciences industry is preparing for the next ...

While all groups have demonstrated an inspiring level of dedication and passion, I have always been moved by patients’ ...

Akeega – which combines the active ingredients in J&J's PARP inhibitor Zejula (niraparib) and androgen blocker Zytiga ...

In a pharmaphorum podcast recorded onsite at the Congress, web editor Nicole Raleigh spoke with Itziar Canamasas, global head ...

The FDA is moving at breakneck speed to roll out a generative artificial intelligence (AI) tool for speeding up regulatory ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

Meanwhile, BioNTech itself bought into the category with its takeover of BNT327's developer Biotheus unit last year for what ...